Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 2,301–2,400 of 2,517
Genetic alterations in astrocytic tumors: hints to a molecular epidemiological interpretation.
Fronza, G., Ottaggio, L., Campomenosi, P., & Abbondandolo, A. (1996) · PubMed
Cell Biology: Research & Therapy
Mu, W., Rückert, F., Niedergethmann, M., Grützmann, R., & Hd, S. (2013)
INDUCTIVE LOGIC AND STATISTICS
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.009
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.014
Knudsen, T. B., & Wubah, J. A. (1998)
Principles of Systemic Cancer Therapy
Thirlwell, C., Bridgewater, J. A., & Cave, J. (2010) · CRC Press eBooks · doi:10.3109/9781841847498-29
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.012
ID4 Acts as a Tumor Suppressor via p53: Mechanistic Insight
Morton, & Derrick, J. P. (2016) · Atlanta University Center Robert W. Woodruff Library (Atlanta University Center Robert W. Woodruff Library)
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.004
Gauch, H. G. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139095082.007
A molecular dissection of neuroinflammation in ovine Batten disease
Chen, Z. (2016) · Lincoln University Research Archive (Lincoln University) · Cited by 1
Somatic Genetic Analysis of p53 Function and Cisplatin Resistance
Gallagher, W. M. (1996) · Enlighten: Theses (The University of Glasgow) · Cited by 1
Protein Folding: From Normal Cellular Function to Pathophysiology
Rasool, M., Malik, A., Manan, A., Sultana, M., Qazi, M. H., & Pushparaj, P. N. (2015) · Springer eBooks · doi:10.1007/978-81-322-2467-9_5
Molecular Dynamics and Stochastic Simulations of Surface Diffusion
Moix, J. M. (2007) · SMARTech Repository (Georgia Institute of Technology)
Study of p53 Gain of Function Mutations in p53-null Astrocytes
Choi, S. H. (2000) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/egvp-cg80
Towards functional multiscale analysis of colorectal cancer
Briffa, R. (2014) · ERA
(1998) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0266-4356(98)90194-2
Biomarkers of environmental exposure: genetic and epigenetic approaches
Scoccianti, C. (2011) · Spiral (Imperial College London) · doi:10.25560/9485
Nichols, K. E., Heath, J. A., Friedman, D., Biegel, J. A., Ganguly, A. A., Mauch, P., & Diller, L. (2003)
Susceptibility genes in hereditary breast cancer
Vahteristo, P. (2003) · Helda - University of Helsinki Institutional Repository
Zhou, H., Hintze, B. J., Kimsey, I. J., et al. (2015)
Regulation of BTRC by gain-of-function TP53 mutation(s) in cancer cells
Xu, W. (2015) · TSpace (University of Toronto)
Visual Analytics Methods for Analyzing Molecular Dynamics Simulations of Mutant Proteins
Bromley, D. (2015) · ResearchWorks at the University of Washington (University of Washington)
Molecular genetic alterations in ovarian cancer
Reles, A. (2001) · edoc Publication server (Humboldt University of Berlin) · doi:10.18452/13801
Investigation of PIN1 as a Genetic Modifier in Li-Fraumeni Syndrome
Villani, A. (2015) · TSpace (University of Toronto)
Characterization and functional analysis of mutant p53 secretome in human cancer
Shakya, R. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.4225/55/58d1bef2e0a57
Letienne, J. (2011) · Repository KITopen (Karlsruhe Institute of Technology) · doi:10.5445/ir/1000024812
“Germ line mutations in p53 contribute to Li–Fraumeni syndrome, which causes predisposition to a diversity of tumors (Hollstein et al., 1994; Cho et al., 1994; Goh et al., 2011).”
BackgroundIdentification of microRNA 302 as an antagonist to p63 expression
Scheel, A. H. (2009) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-769
Uncovering p53 Mutations and Abnormal Gene Expression in Pediatric Adrenocortical Cancer
West, A. N. (2007) · doi:10.21007/etd.cghs.2007.0347
“4 Modeling Structural Effects of the R175L Substitution The residues within the L2 (residues 163-195) and L3 (residues 236-251) loops of the DNA binding domain of p53 coordinate Zn which, in turn, maintains key residues within L3 in a conformation competent for binding DNA (23).”
BackgroundInfluentialCharacterisation of the role of ING5
Basavarajaiah, P., & Lüscher, B. (2005) · RWTH Publications (RWTH Aachen)
An investigation of mutant p53 function.
Noll, J. E. (2011) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
戸口, 侑., Kamada, R., Kanno, M., Imagawa, T., & Sakaguchi, K. (2017) · Chemistry Letters · doi:10.1246/cl.170980
Husaini, R. (2014) · Bradford Scholars (University of Bradford)
Gain-of-function and dominant-negative effects of distinct p53 mutations in lung tumours
Turrell, F. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.18854
“However, p53 activating signals are still required for wild-type p53 activity after 4OHT administration (Christophorou et al., 2005; Martins et al., 2006).”
BackgroundMethodInfluentialIsolan, G. R. (2004) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Understanding p53 structure and targeting mutant p53 for improved cancer therapy
Zhang, Q. (2018) · Figshare
Identification of biological mechanisms by semantic classifier systemsPreprint
Lausser, L. M., Schmid, F. T., Siegle, L., Hühne, R., Buchholz, M., & Kestler, H. A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/335737
“322 The role of p53 in tumor development is frequently discussed in literature [45,46].”
BackgroundMolecular Prognostication of Oral Cavity Squamous Cell Carcinoma by Tissue Microarray Analysis
Alenazi, A. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3610w70z
Barski, M. S. (2018) · BMC Genomics · doi:10.1186/s12864-018-5322-5
Effect of hemin and zinc on experimental colon carcinogenesis in mice
Choi, H.-S., Kim, J., Nam, S.-Y., Yun, Y. W., Jeong, J., & Lee, B. J. (2019) · Journal of Preventive Veterinary Medicine · doi:10.13041/jpvm.2019.43.1.6
Administração Rural - Volume 3
Gomes, A. K., Rodrigues, G. L., da Silva, A. E., et al. (2019) · doi:10.5935/978-85-7042-061-9
Oliveira, D. V. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2019.tde-18022019-101454
An integrative approach uncovers genes with perturbed interactions in cancersPreprint
Kobren, S. N., Chazelle, B., & Singh, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/733485
“sites have been linked to oncogenic activity [28], other binding site mutations are known to entirely 178 disrupt critical interactions and overall protein function [43].”
Backgroundp53 and DNA Damage-Induced Apoptosis in Ovarian Tumour Cell Lines
McIlwrath, A. J. (1997) · Enlighten: Theses (The University of Glasgow)
Knudsen, T. B., & Wubah, J. A. (1998) · Elsevier eBooks · doi:10.1016/b978-012648860-9.50014-5
Detection of R282w P53 Gene Mutation on Exon 8 in Gastric Cancer Patients in Southwest Iran
Afrouz, S., Ghatee, M. A., Roozbehi, A., et al. (2020) · Gene Cell and Tissue · doi:10.5812/gct.103317
“Codon 282 encodes arginine amino acid on the P53 binding site in the central domain during gene expression and makes the minor groove contact (20-22).”
BackgroundCharacterization of NEK10 Tyrosine Kinase Activity in the Cellular Response to DNA Damage
Haider, N. (2018) · TSpace (University of Toronto) · Cited by 1
Informatics Infrastructure for Evidence-Based Cancer Medicine
Bond, J. P., & Luria, S. D. (2006) · Springer eBooks · doi:10.1007/0-387-31056-8_10
Fatakia, S. N. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/213124
“Murine p53 protein interacts with Mdm2 (murine ortholog of MDM2) via its N-terminal as well as core domain [104].”
BackgroundSoto, J., Moody, C., Alhoshani, A., Sánchez-Bonilla, M., Martinon, D., & Cocco, M. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.26.433080
Generating Isogenic Models of Li-Fraumeni Syndrome and Restoring p53 using CRISPR
Tran, J. (2020) · TSpace (University of Toronto)
Terahertz physical mechanism of arsenic (III) restoring p53 mutant protein activity
Tang, C., Zhang, G., Hu, J. S., & Lü, J. (2021) · Acta Physica Sinica · doi:10.7498/aps.70.20210647
Das, P., & Mattaparthi, V. S. K. (2021) · Current Chemical Biology · doi:10.2174/2212796815666210716151211
Investigating molecular targets of the DNA damage response in triple negative breast cancer
Ward, A. (2021) · The University of Queensland · doi:10.14264/662cbf8 · Cited by 1
Homologs of the Tumor Suppressor Protein p53: A Bioinformatics Study for Drug Design.
Thayer, K. M., & Carcamo, C. (2020) · PubMed · Cited by 1
Valenzuela-Chavira, I., Meneses-Sagrero, S. E., Arvizu-Flores, A. A., Hernández-Paredes, J., Rascón-Valenzuela, L. A., Velázquez, C. A., & Robles‐Zepeda, R. E. (2021) · Current Chemical Biology · doi:10.2174/2212796815666211026112056
Structural modulation of p53TAD1-TAZ2 complex upon mutations and post-translational modification
Ghosh, A., & Ganguly, D. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2004235
“There are four important domains of entire p53 (Cho et al., 1994; Clore et al., 1995; Fields & Jang, 1990; Joerger & Fersht, 2007; Lee et al., 1994, 2000; Romer et al., 2006; Wells et al., 2008), namely, transactivation domain (TAD), DNA-binding core domain, tetramerization domain and negative…”
BackgroundRedox regulation of the tumor suppressor p53
Shi, T. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/966 · Cited by 1
Effect of stress during neutron irradiation on the microstructure of type 316 stainless steel
Brager, H. R., Garner, F. A., & Guthrie, G. L. (1976) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Hyperactive p53 leads to age-related phenotypes in mice model
Ou, L. Y. (2009) · eScholarship (California Digital Library)
Redox Regulation of p21, Role of Reactive Oxygen and Nitrogen Species in Cell Cycle Progression
Schönthal, A. H., Mueller, S., & Cadenas, E. (2000) · Elsevier eBooks · doi:10.1016/b978-012636670-9/50016-7 · Cited by 1
Rabinowicz, R., & Malkin, D. M. (2021) · Wiley eBooks · doi:10.1002/9780470015902.a0029375
POSTRANSLATIONAL MODIFICATIONS OF P53: UPSTREAM SIGNALING PATHWAYS.
ANDERSON, C. W. A., & (US), D. (2003) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · doi:10.2172/15006423
(1997) · Elsevier eBooks · doi:10.1016/b978-012639875-5/50017-0
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.003
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.006
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.005
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.011
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.008
Structural-Functional Diversity of p53 Proteoforms
Naryzhny, S., & Legina, O. K. (2019) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s199075081904005x · Cited by 1
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.007
Regulation of the p53 Tumor‐Suppressor Protein by Ubiquitin and Ubiquitin‐Like Molecules
Xirodimas, D. P. (2007) · Wiley eBooks · doi:10.1002/9783527620234.ch2
(1997) · Toxicologic Pathology · doi:10.1177/019262339702500633
(2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.015
Metzler, D. E., Metzler, C. M., & Sauke, D. J. (2001) · Elsevier eBooks · doi:10.1016/b978-012492543-4/50029-5
Gauch, H. G. (2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.002
Bánfalvi, G. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9561-0_4
Portefaix, M., Teulon, I., Nicolas, M., et al. (1997) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/s0923-2532(97)88665-6
Hesketh, R. (1997) · Elsevier eBooks · doi:10.1016/b978-012344548-3/50085-6
A Transgenic Mouse Model for Mammary Carcinogenesis
Murphey, K. L., & Rosen, J. M. (2001) · Springer eBooks · doi:10.1007/978-1-4612-2092-3_18
Lozano, G. (2002) · Wiley eBooks · doi:10.1002/0471203076.emm0273
Kaim, W., & Schwederski, B. E. (2004) · Teubner-Studienbücher. Chemie · doi:10.1007/978-3-322-92714-9_12
Traag, V. (2014) · Springer theses · doi:10.1007/978-3-319-06391-1_6
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
(2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608058204114030007
p53ness in Human Cancers: An Overview
(2016) · ARC Journal of Cancer Science · doi:10.20431/2455-6009.0202003 · Cited by 1
“The accumulating evidence demonstrated that certain cancer-derived mutant forms of p53 transactivate various target genes such as the multiple drug resistance gene 1 (MDR1), c-myc, proliferating cell nuclear antigen (PCNA), interleukin-6 (IL-6), insulin-like growth factor 1 (IGF-1), fibroblast growth factor (FGF) and…”
BackgroundKaim, W., & Schwederski, B. E. (2005) · Teubner-Studienbücher. Chemie · doi:10.1007/978-3-663-01605-2_12
(1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb1294-833
Choi, Y. J., Kim, B., Kim, Y., Shin, S., & Lee, K. (2022) · Laboratory Medicine Online · doi:10.47429/lmo.2022.12.3.145
Molecular Gymnastics Required for Mdmx Inhibition of P53 DNA Binding ActivityPreprint
Fenton, M. J., Borcherds, W. M., Chen, L., Anbanandam, A., Chen, J., & Daughdrill, G. W. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4107498
Kim, J., Jeong, K., Jun, H., Kim, K., Yi, H., Park, S., Woo, G.-U., Lee, D., Kim, T.-Y., Lee, K.-H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1942928/v1
Insights from the p53 induced TIGAR protein 2 in the glycolytic pathway model
Alam, M. J. (2022) · Bioinformation · doi:10.6026/97320630018310
Hyodo, T., Kuribayashi, N., Fukumoto, C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1851167/v1
DISRUPTOR: Computational identification of oncogenic mutants disrupting protein interactionsPreprint
Kugler, V., Lieb, A., Guerin, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.02.514903
Ianni, A. D., Tüting, C., Kipping, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.11.516092
“Single-molecule FRET (smFRET) experiments from the same study also showed a spatial proximity between the very C terminus of p53 and the L1-loop (residues 112–124) within the DBD in presence of RE-DNA.”
InfluentialTranscription Factor – DNA Complexes
Helms, V. (2022) · Wiley eBooks · doi:10.1002/9783527830503.ch10
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.